PERSON TO FOLLOW

Sharon Rosenzweig-Lipson

Chief Scientific Officer, Life Biosciences

Chief scientific officer of Life Biosciences, the company developing ER-100, a partial epigenetic reprogramming therapy for optic neuropathies. She presented the first human data from the ER-100 Phase 1 trial at Eyecelerator @ AAO 2026.

epigenetic reprogrammingoptic neuropathiesglaucomacellular rejuvenation

WHAT TO WATCHResults from the higher Dose Level 2 cohort and the first data in NAION patients.

ON THE WIRE

Every story about Sharon’s work.

Clinical TrialsFirst human test · 3 people

Gene therapy that aims to make eye cells act younger is tried in 3 people

Three people with glaucoma had no serious side effects in the eight weeks after a single eye injection, and two showed some improvement in their field of vision, Life Biosciences said. It is a very early, company-reported result.

David Sinclair SRSharon Rosenzweig-Lipson8 sources · 5 min

Profile sources

1
Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies Life Biosciences, Inc.
2
FDA clears investigational new drug application for ER-100 healio.com
3
Life Biosciences to Present First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies at Eyecelerator 2026 GlobeNewswire News Room